Work

Abstract CT252: transcendIT-101: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct252

Authors: Diwakar Davar, Stina M. Singel, Gil Nyamuswa, Tuan-Anh Tran, Yang Wu, Jaspreet Grewal, Morteza Aghmesheh, Alexander Spira, Vinod Ganju, Jamie Rand, Sophia Frentzas, David Bajor, Nashat Gabrail

Institutions: University of Pittsburgh Medical Center, Norton Healthcare, Virginia Cancer Specialists, City Of Hope National Medical Center, Monash Health, University Hospitals Cleveland Medical Center, Gabrail Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282912962

Cites:

Cited by: 1

Related to: 10